General form of registration statement for all companies including face-amount certificate companies

Commitments and Contingencies - Additional Information (Detail)

v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
 0 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended
Oct. 16, 2012
Oct. 31, 2012
Nov. 30, 2013
May 31, 2013
May 31, 2012
Commitment And Contingencies [Line Items]          
Cash severance payment     $ 276,000 $ 479,000  
Option immediate vesting     50,000 780,000 527,500
Severance liabilities       365,000  
Stock based compensation expense       1,128,000  
Asset purchase, cash paid   3,500,000      
Asset Purchase Agreement Aggregate Consideration Paying Period 10 years     10 years  
Progenics Pharmaceuticals, Inc
          
Commitment And Contingencies [Line Items]          
Royalty on every net sales 5.00%     5.00%  
Initial Payment
          
Commitment And Contingencies [Line Items]          
Asset purchase, cash paid 3,500,000     3,500,000  
Milestone Payments | US Phase III trial
          
Commitment And Contingencies [Line Items]          
Asset purchase, cash paid 1,500,000     1,500,000  
Milestone Payments | US new drug application approval by the FDA
          
Commitment And Contingencies [Line Items]          
Asset purchase, cash paid 5,000,000     5,000,000  
Development Milestone Payments
          
Commitment And Contingencies [Line Items]          
Royalty on every net sales 7.50%     7.50%  
Asset Purchase Agreement Aggregate Consideration Paying Period 10 years     10 years  
Minimum annual license maintenance fees 150,000     150,000  
Development Milestone Payments | US Phase III trial
          
Commitment And Contingencies [Line Items]          
Asset purchase, cash paid 1,000,000     1,000,000  
Development Milestone Payments | US new drug application approval by the FDA
          
Commitment And Contingencies [Line Items]          
Asset purchase, cash paid 500,000     500,000  
Development Milestone Payments | New Drug Application with the FDA
          
Commitment And Contingencies [Line Items]          
Asset purchase, cash paid 500,000     500,000  
Director
          
Commitment And Contingencies [Line Items]          
Salary     13,890 13,890  
Cash severance payment     $ 13,890 $ 13,890  
Severance period     33 months 33 months  
Reimbursement of health insurance period     9 months 9 months  
Director | Stock Option Award Agreement dated Dec 6,2010
          
Commitment And Contingencies [Line Items]          
Stock option award agreement     500,000 500,000  
Stock Option granted     $ 1.19 $ 1.19  
Director | Stock Option Award Agreement dated September 22,2010
          
Commitment And Contingencies [Line Items]          
Options granted     25,000 25,000  
Director | Stock Option Award Agreement dated April 16,2012
          
Commitment And Contingencies [Line Items]          
Stock option award agreement     750,000 750,000  
Stock Option granted     $ 2.00 $ 2.00  
Option immediate vesting     1,500,000 1,500,000  
Options forfeiture     750,000 750,000